Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of IV-Globulin SN 10% in immune thrombocytopenia
KCT0001026Phase 3Not yet recruiting
- Sponsor
- GC Biopharma
- Start
- Mar 2014
- Countries
- 1
01
Overview
A Phase 3 trial of ALYGLO in immune thrombocytopenia (ITP), sponsored by GC Biopharma. Planned start Mar 2014; status: not yet recruiting.
02
Drugs
ALYGLO
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on KCT0001026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001026.